Drug assessment at a glance: A25-158[1]

Nirmatrelvir/ritonavir (COVID-19, ≥ 6 years to < 18 years, ≥ 20 kg)

20 July 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A25-158. The G-BA decides on the added benefit.

Research question 1 of the benefit assessment

Population	Children and adolescents aged 6 to ≤ 17 years, and weighing between 20 and 40 kg, with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
Intervention	nirmatrelvir/ritonavir
Comparator	BSC
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects – research question 1

	Size of the effects	Informative value of the effects
Mortality	∅	–
Morbidity	∅	–
Symptoms	∅	–
Health-related quality of life	∅	–
Side effects	∅	–
	∅ No (suitable) data ↔ No advantage or disadvantage ↑ / ↓ Small advantage/disadvantage ↑↑ / ↓↓ Moderate advantage/disadvantage ↑↑↑ / ↓↓↓ Large advantage/disadvantage	– Not applicable ★ Low ★★ Moderate ★★★ High

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects – research question 1

- No relevant study was identified.

Research question 2 of the benefit assessment

Population	Children and adolescents aged 6 to ≤ 17 years, and weighing at least 40 kg, with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19
Intervention	nirmatrelvir/ritonavir
Comparator	remdesivir
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects – research question 1

	Size of the effects	Informative value of the effects
Mortality	∅	–
Morbidity	∅	–
Symptoms	∅	–
Health-related quality of life	∅	–
Side effects	∅	–
	∅ No (suitable) data ↔ No advantage or disadvantage ↑ / ↓ Small advantage/disadvantage ↑↑ / ↓↓ Moderate advantage/disadvantage ↑↑↑ / ↓↓↓ Large advantage/disadvantage	– Not applicable ★ Low ★★ Moderate ★★★ High

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects – research question 2

- No relevant study was identified.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nirmatrelvir/Ritonavir (COVID-19, ≥ 6 Jahre bis < 18 Jahre, ≥ 20 kg); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 30.06.2026]. URL: https://doi.org/10.60584/A25-158.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Nirmatrelvir/Ritonavir (Coronavirus-Krankheit 2019 (COVID-19)) [online]. 2026 [Accessed: 30.06.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1296/.

English translations for this project are published at https://www.iqwig.de/en/projects/a25-158.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de